Antigenic Change in Human Influenza A(H2N2) Viruses Detected by Using Human Plasma from Aged and Younger Adult Individuals.
H2N2
aged individuals
antigenic change
antigenic drift
influenza A virus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
23 10 2019
23 10 2019
Historique:
received:
30
09
2019
revised:
21
10
2019
accepted:
21
10
2019
entrez:
27
10
2019
pubmed:
28
10
2019
medline:
2
10
2020
Statut:
epublish
Résumé
Human influenza A(H2N2) viruses emerged in 1957 and were replaced by A(H3N2) viruses in 1968. The antigenicity of human H2N2 viruses has been tested by using ferret antisera or mouse and human monoclonal antibodies. Here, we examined the antigenicity of human H2N2 viruses by using human plasma samples obtained from 50 aged individuals who were born between 1928 and 1933 and from 33 younger adult individuals who were born after 1962. The aged individuals possessed higher neutralization titers against H2N2 viruses isolated in 1957 and 1963 than those against H2N2 viruses isolated in 1968, whereas the younger adults who were born between 1962 and 1968 possessed higher neutralization titers against H2N2 viruses isolated in 1963 than those against other H2N2 viruses. Antigenic cartography revealed the antigenic changes that occurred in human H2N2 viruses during circulation in humans for 11 years, as detected by ferret antisera. These results show that even though aged individuals were likely exposed to more recent H2N2 viruses that are antigenically distinct from the earlier H2N2 viruses, they did not possess high neutralizing antibody titers to the more recent viruses, suggesting immunological imprinting of these individuals with the first H2N2 viruses they encountered and that this immunological imprinting lasts for over 50 years.
Identifiants
pubmed: 31652870
pii: v11110978
doi: 10.3390/v11110978
pmc: PMC6893718
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Déclaration de conflit d'intérêts
Y.K. has received speaker’s honoraria from Toyama Chemical and Astellas Inc.; has received grant support from Chugai Pharmaceuticals, Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Otsuka Pharmaceutical Co., Ltd., and Denka Seiken Co., Ltd.; and is a co-founder of FluGen. Y.Arai. has received a research grant from Daiichi Sankyo Co, Ltd. and Novartis Pharma K K. The other authors have no conflicts of interest.
Références
Nature. 2011 Mar 10;471(7337):157-8
pubmed: 21390107
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
J Virol. 2015 Apr;89(7):3763-75
pubmed: 25609810
J Infect Dis. 2016 Jan 1;213(1):31-8
pubmed: 26142433
Nature. 2009 Jun 18;459(7249):931-9
pubmed: 19525932
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
J Clin Virol. 2018 Nov;108:105-111
pubmed: 30292135
J Virol. 2019 Apr 3;93(8):
pubmed: 30700609
Arch Virol. 1984;81(3-4):239-50
pubmed: 6477129
J Virol. 2012 Jun;86(11):6334-40
pubmed: 22457520
Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4
pubmed: 30308159
EBioMedicine. 2017 Mar;17:182-191
pubmed: 28286060
J Virol. 2015 Feb;89(4):2442-7
pubmed: 25505070
J Virol. 2010 Aug;84(15):7695-702
pubmed: 20504935
Virology. 1984 Oct 30;138(2):276-86
pubmed: 6208682
J Infect Dis. 2018 Aug 24;218(7):1054-1060
pubmed: 29762672
J Gen Virol. 2001 Oct;82(Pt 10):2475-84
pubmed: 11562540
Comput Appl Biosci. 1992 Jun;8(3):275-82
pubmed: 1633570